The American Diabetes Association (ADA) 2024 Standards of Care support GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists, including tirzepatide, particularly in patients with: Established atherosclerotic cardiovascular disease or high cardiovascular risk Chronic kidney disease Need for substantial A1c reduction (tirzepatide typically reduces A1c by 1.5-2.5%) Desire to avoid weight gain or achieve weight loss Inadequate glycemic control on metformin or other oral agents Tirzepatide is not approved for type 1 diabetes or diabetic ketoacidosis
Were not trying to tell people not to lose weight and not to take certain medication, but we are trying to help people to make a more educated decision
The length of your treatment depends on your weight loss goals, how your body responds to the injections, and whether you are combining the shots with other weight management strategies
This support means you can focus entirely on health improvements rather than administrative details
Methods 18 , 100106 (2021)
We review your weight-loss history, current struggles, and lab results to create a treatment plan that fits your goals and your budget